Grants for For profit organizations other than small businesses - Science and Technology

The City of Takoma Park’s Community Quality of Life Grants Program aims to enhance the well-being of its residents by supporting programs, projects, and events that increase access and opportunities in the arts and sciences. This initiative aligns with a broader mission to foster community engagement and enrichment, ensuring that residents have avenues to participate in and benefit from cultural and educational activities. The program seeks to create a vibrant community where residents can thrive through diverse experiences in the arts and sciences. The primary beneficiaries of this grant program are residents of the City of Takoma Park, with specific requirements ensuring that at least 75% of participants are city residents and at least 51% are from low-to-moderate income households (defined as 80% of the Area Median Income). The impact goals are centered on improving the quality of life by expanding access and participation in the arts and sciences, particularly for those who may face economic barriers. This focus on inclusive access aims to bridge gaps in opportunity and ensure that a broad segment of the community can benefit from these enriching experiences. The program prioritizes projects falling into one of three categories: Arts and Humanities (A&H), Science, Technology, Engineering, and Math (STEM), and Science, Technology, Engineering, Arts, and Math (STEAM). This broad focus allows for a diverse range of initiatives that can contribute to the program's overall goals. The emphasis on these specific areas reflects a strategic approach to community development, recognizing the importance of both creative and scientific literacy in fostering a well-rounded and engaged populace. Expected outcomes include increased participation of Takoma Park residents, especially those from low-to-moderate income households, in arts and science programs. Measurable results will likely involve tracking participant numbers, demographic information, and the successful completion of funded projects between July 1, 2024, and June 30, 2025. The program operates under a theory of change that by providing financial support to local organizations offering such programs, the City can directly influence and improve the quality of life for its residents, fostering a more equitable and culturally rich community.

The GO Laurel Highlands is offering a tourism grant ranging from $10,000 to $100,000 for marketing, enhancement of attractions, and special events aimed at increasing visitation and economic activity in Westmoreland County, Pennsylvania, with applications to be submitted by October 4, 2024.

This program provides funding to interdisciplinary teams working with communities to develop and implement innovative solutions for regional climate challenges across the U.S.

The purpose of this document is to advise the public that the NOAA RESTORE Science Program is soliciting proposals for projects of five years in duration with the option for a five year, non-competitive renewal award for high-performing projects. This announcement invites proposals that request funding for partnerships that include researchers, resource managers, and other interested parties to conduct a collaborative research project that will identify, track, understand, or predict trends and variability in the Gulf of Mexicos natural resources and the abiotic and biotic factors driving those trends. Funding is contingent upon the availability of funds in the Gulf Coast Restoration Trust Fund. It is anticipated that final recommendations for funding under this Announcement will be made in June 2025, and that projects funded under this Announcement will have a October 1, 2025 start date. Total funding for this competition will be approximately $17.5 million over five years and approximately six projects may be funded. The minimum individual award amount is approximately $1 million over five years (an average of $200,000 per year) and the maximum individual award amount is approximately $4 million over five years (an average of $800,000 per year). An additional $21 million may be available for five year, non-competitive renewals for high performing projects. Information regarding this Announcement, including webinars and additional background information, is available on the Science Programs website (https://restoreactscienceprogram.noaa.gov/funding-opportunities/ffo-2025).The NOAA RESTORE Science Program encourages applicants and awardees to support the principles of diversity, equity, and inclusion when writing their proposals and performing their work. Promoting diversity, inclusion, and equity improves the creativity, productivity, and vitality of the research and management communities and leads to more robust natural resource management decisions.Electronic Access: The NOAA RESTORE Science Program website (http://restoreactscienceprogram.noaa.gov/) furnishes supplementary information. Full proposals should be submitted electronically through Grants.gov (http://www.grants.gov).

The Commission on the Arts and Humanities (CAH) Fiscal Year 2025 Art Bank Program is a grant initiative designed to support local visual artists, District art galleries, and art nonprofit organizations by acquiring fine art. This ongoing annual acquisition program contributes to the Art Bank Collection, which began in 1986 and currently holds nearly 3,000 artworks. The mission of this program aligns with CAH's overall goal to foster artistic and cultural development within the District of Columbia and its metropolitan region. The acquired artwork is then loaned to District Government agencies for public display, thereby enhancing public spaces and offices within government buildings. The primary target beneficiaries of this program are qualified artists and District nonprofit art galleries or organizations representing metropolitan artists. The impact goals are multi-faceted: to grow the District's art collection to reflect the diverse artistic history and communities of the region, to provide support, exposure, and professional benefits for visual artists, and to enhance the aesthetic experience for District employees and visitors in government buildings. CAH seeks to achieve these goals through the acquisition of original two- and three-dimensional artwork, including ceramics, drawings, fabric arts, mixed media works, paintings, photographs, prints, and sculptures. The program's priorities and focuses are clearly defined. For individual artists, eligibility requires being aged 18 or older, a legal resident of Washington, DC, or within a 50-mile radius for at least one year, maintaining primary residency during the funding period (October 1, 2024 – September 30, 2025), having a permanent DC, MD, or VA address, and being in good standing with CAH. Nonprofit galleries and organizations must be 501(c)(3) incorporated, represent metropolitan artists, have a principal business office in DC, be registered to do business in the District, ensure at least 51% of activities occur in DC, have an active Board of Directors, obtain "Citywide Clean Hands" certification, and also be in good standing with CAH. Expected outcomes and measurable results include the expansion of the Art Bank Collection with diverse artworks, an increase in professional opportunities and visibility for local artists, and an improved aesthetic environment in District government buildings and public spaces. Award amounts vary, with individual applicants potentially receiving up to $15,000 and nonprofit art galleries or organizations up to $20,000, for a grant duration of one year. This structured funding approach, combined with stringent eligibility, is central to CAH's strategic priorities of enriching the District's cultural landscape and supporting its artistic community, operating under a theory of change that direct investment in art acquisition and artist support will yield significant cultural and public benefits.

This program provides financial assistance to homeowners in Dearborn for the rehabilitation, repair, or replacement of damaged porches and outdoor steps.

This program provides funding to various organizations to expand high-speed internet access in underserved areas of Illinois, focusing on improving connectivity for schools, libraries, and health facilities.

This initiative provides financial and technical support to small businesses in Detroit that have been operating for 30 years or more, recognizing their cultural and economic contributions to the community.

The Northwestern STEM Network Grant VI, administered by the Nevada Governor’s Office of Science, Innovation, and Technology (OSIT), aims to support innovative initiatives that align with the objective of developing a diverse talent pool to meet the employment needs of Northwestern Nevada’s evolving STEM industries. Projects should address equity in STEM, raise awareness about STEM opportunities, and ensure high-quality STEM education with engaged business partners across all counties, cities, and districts. Funding is available up to $50,000, with applications due by June 28, 2024. Eligible projects include pilot programs, scaling up existing programs, or extending successful initiatives from other regions.

This program provides funding for interdisciplinary research projects that improve American infrastructure by integrating social sciences with STEM fields, targeting institutions, nonprofits, and businesses dedicated to enhancing societal wellbeing and economic growth.

This funding opportunity provides financial support to eligible contractors for developing renewable energy and energy efficiency projects that benefit low-income communities and promote workforce training in Illinois.

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are:Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a fundamentally new approach that is significantly more effective than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research.Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the program announcement, and not on the amount of the budget.The current program announcement discusses the Breakthrough Award Level 4. Funding Levels 1, 2, and 3 are available under other program announcements (HT942524BCRPBTA12 for Levels 1 and 2 and HT942524BCRPBTA3 for Level 3). The PI is strongly encouraged to review the research scope defined under each funding level as described in the corresponding Breakthrough Award program announcements before submitting the pre-application. An application that does not meet the intent of Funding Level 4 will not be recommended for funding, even if it might meet the intent of a different funding level.The following is a general description, although not all-inclusive, of the scope of research projects that would be appropriate to propose under the current program announcement:Funding Level 4: Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer. Human clinical trials are required. Large-scale trials, such as comparative effectiveness clinical trials, that will transform and revolutionize the clinical management and/or prevention of breast cancer and lead to unprecedented impact on patients lives, may fall under this mechanism. PIs are expected to have experience in successfully leading large-scale projects and demonstrated ability (through personal experience or via a commitment from a collaborating clinical investigator) to implement a clinical trial successfully. Where relevant, applications must demonstrate availability of and access to necessary data, human samples, cohort(s), and/or critical reagents. For proposed research that will require U.S. Food and Drug Administration (FDA) involvement, project readiness requirements at the time of application submission include: proof of availability of and access to clinical reagents (e.g., therapeutics) that meet regulatory compliance guidelines, proof of availability of and access to appropriate subject population(s), validated projections for patient recruitment, and submission of an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the FDA, if applicable.Funding from this award mechanism must support a clinical trial. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For more information, a Human Subject Resource Document is provided at https://cdmrp.health.mil/pubs/pdf/Human%20Subjects%20Resource%20Document_DEC2022.pdf.Note: An invited oral presentation is a requirement for application review of Funding Level 4 projects, as described in Section II.D.2.b, Full Application Submission Content.Partnering PI Option: The Breakthrough Award encourages applications that include meaningful and productive partnerships between investigators. The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development of the proposed research project including the Project Narrative, Statement of Work (SOW), and other required components. The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application. The application should clearly demonstrate that both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project. It is expected that funding will be balanced between both PIs unless appropriately justified. New partnerships are encouraged, but not required. The application is expected to describe how the PIs unique expertise combined as a partnership will better address the research question, how the unique expertise that each individual brings to the application is critical for the research strategy and completion of the SOW, and why the work should be done together rather than through separate efforts. To meet the intent of the Partnering PI Option, applicants are discouraged from being named as a Partnering PI on multiple Breakthrough Award Level 4 applications unless they are clearly addressing distinct research questions. Applications where one PI is providing samples or investigational agents while the other PI is performing most or all of the research and analyses do not meet the intent of the Partnering PI Option. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PIs, refer to Section II.D.2, Content and Form of the Application Submission.Personnel: Applications are expected to include an appropriate and robust research team with the combined backgrounds and breast cancer-related expertise to enable successful conduct of the project.Consumer Advocates: Applications are required to include consumer advocate involvement. The research team must include two or more breast cancer consumer advocates, who will be integral throughout the planning and implementation of the research project. Consumer advocates should be involved in the development of the research question, project design, oversight, recruitment, and evaluation, as well as other significant aspects of the proposed project. Interactions with other team members should be well integrated and ongoing, not limited to attending seminars and semi-annual meetings. As lay representatives, the consumer advocates must be individuals who have been diagnosed with breast cancer, and they should be active in a breast cancer advocacy organization. Their role in the project should be independent of their employment, and they cannot be employees of any of the organizations participating in the application. Their role should be focused on providing objective input on the research and its potential impact for individuals with, or at risk for, breast cancer. The consumer advocates should have a high level of knowledge of current breast cancer issues and the appropriate background and/or training in breast cancer research to contribute to the project.Key Aspects of the BCRP Breakthrough Award Level 4 Mechanism: Preliminary data are required: Inclusion of preliminary data relevant to the proposed clinical trial is required. Study Population: The application should demonstrate the availability of and access to a suitable patient population that will support a meaningful outcome for the study. The application should include a discussion of how accrual goals will be achieved, as well as the strategy for inclusion of women and minorities in the clinical trial appropriate to the objectives of the study. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, gender, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. Intervention Availability: The application should demonstrate the documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study. Personnel and Environment: The application should demonstrate the study teams expertise and experience in all aspects of conducting clinical trials, including appropriate statistical analysis, knowledge of FDA processes (if applicable), and data management. The application should include a study coordinator(s) who will guide the clinical protocol through the local IRB of record and other federal agency regulatory approval processes, coordinate activities from all sites participating in the trial, and coordinate participant accrual. The application should show strong institutional support and, if applicable, a commitment to serve as the FDA regulatory sponsor, ensuring all sponsor responsibilities described in the Code of Federal Regulations, Title 21, Part 312 (21 CFR 312), Subpart D, are fulfilled. Statistical Analysis and Data Management Plans: The application should include a clearly articulated statistical analysis plan, a power analysis reflecting sample size projections that will answer the objectives of the study, and a data management plan that includes use of an appropriate database to safeguard and maintain the integrity of the data. If required by a Regulatory Agency, the trial must use a 21 CFR 11-compliant database and appropriate data standards.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 BCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. Collaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the partners bring to the research effort, ultimately advancing cancer research that is of significance to the Warfighter, military Families, and the American public.For the purposes of this funding opportunity, Regulatory Agency refers to the FDA or any relevant international regulatory agency unless otherwise noted.If the proposed clinical trial involves the use of a drug that has not been approved by the relevant Regulatory Agency for the country where the research will be conducted, then submission of an IND application, or equivalent, that meets all requirements under 21 CFR 312 may be required. It is the responsibility of the applicant to provide evidence from the IRB of record or the relevant Regulatory Agency if an IND, or equivalent, is not required. If an IND, or equivalent, is required, the regulatory application must be submitted to the relevant regulatory agency by the Breakthrough Award Level 4 application submission deadline. The IND, or equivalent, should be specific for the product and indication to be tested in the proposed clinical trial. For more information on IND applications specifically, the FDA has provided guidance at https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application.If the investigational product is a device, then submission of an IDE, or equivalent, application that meets all requirements under 21 CFR 812 may be required. It is the responsibility of the applicant to provide evidence if an IDE, or equivalent, is not required. If an IDE, or equivalent, is required, the IDE application, or equivalent, must be submitted to the relevant Regulatory Agency by the Breakthrough Award Level 4 application submission deadline. The IDE, or equivalent, should be specific for the device and indication to be tested in the proposed clinical trial.The types of awards made under the program announcement will be cooperative agreements (31 USC 6305) based on anticipated substantial involvement on the part of CDMRP. Substantial involvement includes assistance, guidance, coordination, and/or participation by CDMRP staff in project activities, including but not limited to, Milestone Meetings wherein recommendations for continued funding will be made based on overall study progress.The anticipated direct costs budgeted for the entire period of performance for an FY24 BCRP BTA4 should not exceed $15M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $23.3M to fund approximately one Breakthrough Award Level 4 application. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The Indiana Office of Energy Development seeks proposals for Empowering Energy Partnerships in Indiana Communities to address energy needs at a community or regional scale. The program supports comprehensive solutions aligned with the state’s pillars of reliability, resiliency, stability, affordability, and environmental sustainability, and encourages partnerships with measurable public benefits. Eligible project topics include energy efficiency such as building upgrades and energy management technologies, alternative fueling and charging infrastructure that is publicly accessible, energy security and reliability including backup generation, microgrids, and cybersecurity, and clean energy resources such as solar, storage, geothermal, wind, and biomass. Vehicle purchases and certain high speed charging are not allowable under program rules. Projects should also demonstrate connections to state priorities such as economic development, workforce development, education, and public safety. Eligible entities include local units of government, nonprofit organizations, for profit entities, and institutions of higher education that are Indiana based and registered federally and with the state. Approximately 2,500,000 dollars is available, with anticipated awards averaging 300,000 to 500,000 dollars for project periods of up to three years. One proposal per eligible entity is allowed; applicants may coordinate regional submissions but cannot make tiered subawards. Applications are due May 1, 2024 through the state’s process. Additional information is available from the Indiana Office of Energy Development.

This funding opportunity supports scientific research projects that evaluate the effectiveness of California's forest management regulations, targeting a wide range of applicants including government agencies, educational institutions, and nonprofit organizations focused on sustainable land management.

This competition provides funding and flight testing opportunities for U.S.-based individuals, teams, and organizations to develop innovative space technologies that address critical challenges identified by NASA.

The DOD Traumatic Brain Injury and Psychological Health, Emerging Topics Research Award aims to accelerate research in traumatic brain injury and psychological health, with the goal of developing new clinical applications, health care products, and guidelines for Service Members, their Families, Veterans, and the American public.

This funding opportunity supports two established melanoma researchers to co-lead a virtual network that mentors and develops early-career melanoma researchers through collaborative initiatives and professional growth.

The "DoD Rare Cancers, Idea Development Award" is a grant aimed at supporting early-stage research ideas with high potential impact, which could lead to significant advancements in the diagnosis, treatment, and improved health outcomes for individuals suffering from rare cancers, with a particular focus on innovative research involving nuclear medicine, women's health, and adherence to rigorous study design standards.

This funding opportunity supports innovative research aimed at preventing Alzheimer’s disease and related dementias, particularly in relation to military service and traumatic brain injury, targeting independent researchers from various eligible organizations.

This initiative seeks input from various stakeholders, including businesses, researchers, and government entities, to enhance the recycling and reuse of products and materials, ultimately promoting environmental sustainability and economic resilience.